Yu-Waye Chu is VP at FATE THERAPEUTICS INC (FATE). They have made 8 open-market trades across 2 companies since 2021, most recently 2026-03-17.
CIK 0001854586
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CTMX | 189,446 | $432K |
| FATE | 140,676 | $250K |
| Total | $682K |
Shares reported on the most recent Form 4, priced at the 2026-03-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTMX | SELL | 2026-03-17 | 2026-03-19 | $6.42 | $273K | +1.7% | +6.0% | -36.0% |
| CTMX | SELL | 2025-03-18 | 2025-03-20 | $0.60 | $2K | -10.1% | +16.3% | +227.1% |
| FATE | SELL | 2023-04-18 | 2023-04-19 | $6.57 | $17K | +0.3% | -21.5% | -27.6% |
| FATE | SELL | 2023-01-10 | 2023-01-11 | $5.24 | $41K | -5.2% | +8.6% | -1.6% |
| FATE | SELL | 2022-04-19 | 2022-04-21 | $35.37 | $287K | -16.1% | -34.1% | -4.9% |
| FATE | SELL | 2022-01-11 | 2022-01-13 | $48.48 | $364K | -5.3% | -12.2% | -6.1% |
| FATE | SELL | 2021-12-10 | 2021-12-13 | $51.39 | $693K | +37.0% | -4.0% | -36.8% |
| FATE | SELL | 2021-04-16 | 2021-04-20 | $83.30 | $273K | +13.3% | +0.2% | +4.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.